{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:58:16Z","timestamp":1785167896272,"version":"3.55.0"},"reference-count":34,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.1080\/13543776.2022.2113873","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:58:08Z","timestamp":1660388288000},"page":"933-937","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018\/127207 and WO2020\/007355) for the treatment of herpes simplex virus infections \u2013 structure proposal for Phaeno Therapeutics drug candidate HN0037"],"prefix":"10.1080","volume":"32","author":[{"given":"Christian","family":"Gege","sequence":"first","affiliation":[{"name":"Innovative Molecules GmbH, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Kleymann","sequence":"additional","affiliation":[{"name":"Innovative Molecules GmbH, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"cit0001","volume-title":"Fields virology","author":"Knipe DM","year":"2013","edition":"6"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.006"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.827663"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13948"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.3390\/v13081547"},{"key":"cit0007","unstructured":"Maruho files for additional indication and dosage\/administration for anti-herpes virus agent \u201cAmenalief\u00ae Tab. 200mg\u201d for the treatment of recurrent herpes simplex in Japan. [cited 2022 Mar 7]. Available from: www.maruho.co.jp\/english\/information\/20211214_pr_eng.pdf"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301150"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00183"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1177\/09564624211006568"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8668"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105190"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1766-1772.2002"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.002"},{"key":"cit0016","unstructured":"Medshine Discovery Inc. Thiazole derivative and applications thereof. WO2018127207; 2018"},{"key":"cit0017","unstructured":"Medshine Discovery Inc. Crystal forms of thiazole compound and application thereof. WO2020007355; 2020"},{"key":"cit0018","unstructured":"Phaeno Therapeutics company website. [cited 2022 Feb 6]. Available from: www.phaenothera.com"},{"key":"cit0019","unstructured":"Rutzer C, Niggli M What\u2019s next? The swiss pharmaceutical industry in the international innovation race. [cited 2022 Feb 6]. Available from: https:\/\/innoscape.ch\/de\/publikationen\/swiss-pharma-international-innovation-race"},{"key":"cit0020","unstructured":"Bayer AG. Thiazolyl amide derivates. WO2001047904; 2001."},{"key":"cit0021","unstructured":"Bayer AG. Thiocarbonyl-derivate. DE10044328; 2002."},{"key":"cit0022","unstructured":"Aicuris GmbH & Co. KG. N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate. WO2013045479; 2013."},{"key":"cit0023","unstructured":"Aicuris Anti-Invective Cures GmbH. N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide free base hemihydrate, methods of manufacture and uses thereof. WO2018096170; 2018."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00233B"},{"key":"cit0025","unstructured":"Aicuris Anti-Invective Cures GmbH. Topical pharmaceutical formulation comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide. WO2018095576; 2018."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1021\/jm201706b"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2008.03.019"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/0272-0590(92)90206-W"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1177\/019262339202000111"},{"key":"cit0030","unstructured":"Aicuris GmbH & Co. KG. Helicase-primase inhibitors for use in a method of treating Alzheimer\u2019s disease. WO2014124978. 2014."},{"key":"cit0031","unstructured":"Aicuris Anti-Invective Cures GmbH. A maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses. WO2018096177. 2018."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049470"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.4155\/ppa-2017-0039"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060679"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2113873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T13:56:24Z","timestamp":1662558984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2113873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,2]]}},"alternative-id":["10.1080\/13543776.2022.2113873"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2113873","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}